Faissner, Simon http://orcid.org/0000-0002-3412-762X
Plemel, Jason R. http://orcid.org/0000-0003-1385-1464
Gold, Ralf
Yong, V. Wee http://orcid.org/0000-0002-2600-3563
Article History
Accepted: 4 July 2019
First Online: 9 August 2019
Competing interests
: S.F. and V.W.Y. have filed provisional patent applications at the US Food and Drug Administration (US patent application no. 62/412,555, entitled ‘Combination Therapy with Minocycline and Hydroxychloroquine for the Treatment of Multiple Sclerosis (MS)’ and US patent application no. 62/412,534, entitled ‘Treatment for Progressive Multiple Sclerosis’). S.F. has received travel support from Biogen Idec and Genzyme, speaker’s honoraria from Novartis, board honoraria from Celgene and grant support from Novartis, unrelated to this article. J.R.P. declares no competing interests. R.G. has received speaker’s and board honoraria from Baxter, Bayer Schering, Biogen Idec, CLB Behring, Genzyme, Merck Serono, Novartis, Stendhal, Talecris and Teva. His department has received grant support from Bayer Schering, BiogenIdec, Genzyme, Merck Serono, Novartis and Teva. All of R.G.’s declarations are unrelated to the content of this article. V.W.Y. has received speaker’s and advisory board honoraria from Biogen, EMD Serono, Roche, Novartis, Sanofi-Genzyme and Teva, and educational grants from Biogen, EMD Serono, Roche, Novartis, Sanofi-Genzyme and Teva.